Related Experiment Video
Updated: Aug 14, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet drugs in cardiovascular diseases
Insights
Antiplatelet agents are crucial for managing atherothrombotic conditions by inhibiting platelet aggregation. This review examines the evidence for their use in thrombosis and associated concerns.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Platelets are central to atherothrombotic disease pathogenesis, including acute coronary syndromes and cerebrovascular events.
- Antiplatelet drugs target platelet activation and aggregation, potentially altering cardiovascular disease progression.
Purpose of the Study:
- To review the evidence supporting the use of antiplatelet agents in various thrombotic conditions.
- To summarize concerns related to the clinical application of antiplatelet therapy.
Main Methods:
- Literature review of studies on antiplatelet agents in thrombotic diseases.
- Analysis of evidence for monotherapy and combination therapy.
Main Results:
- Evidence supports the use of antiplatelet agents in managing atherothrombotic events.
- The review synthesizes data on efficacy and safety profiles.
Conclusions:
- Antiplatelet therapy is a cornerstone in preventing and treating thrombotic cardiovascular diseases.
- Careful consideration of risks and benefits is essential for optimal patient outcomes.
Abstract:
Platelets play a key role in the pathogenesis of atherothrombotic conditions, e.g. acute coronary syndromes, cerebrovascular and peripheral vascular events. Antiplatelet agents interfere with platelet activation and aggregation and, as such, would be expected to modify the natural history of cardiovascular disease. In this review we explore the evidence to support the use of such drugs, singly or in combination, in a variety of situations characterised by thrombosis and summarise some of the concerns inherent in their use.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care

